AU6872691A - Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans - Google Patents

Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans

Info

Publication number
AU6872691A
AU6872691A AU68726/91A AU6872691A AU6872691A AU 6872691 A AU6872691 A AU 6872691A AU 68726/91 A AU68726/91 A AU 68726/91A AU 6872691 A AU6872691 A AU 6872691A AU 6872691 A AU6872691 A AU 6872691A
Authority
AU
Australia
Prior art keywords
sulfate
glycans
inhibition
cell growth
keratan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU68726/91A
Inventor
Adrian Harel
Dikla Roufa
Jerry Silver
Diane M Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of AU6872691A publication Critical patent/AU6872691A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU68726/91A 1989-10-27 1990-10-26 Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans Abandoned AU6872691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42837489A 1989-10-27 1989-10-27
US428374 1989-10-27

Publications (1)

Publication Number Publication Date
AU6872691A true AU6872691A (en) 1991-05-31

Family

ID=23698624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68726/91A Abandoned AU6872691A (en) 1989-10-27 1990-10-26 Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans

Country Status (4)

Country Link
EP (1) EP0493533A4 (en)
AU (1) AU6872691A (en)
CA (1) CA2071898A1 (en)
WO (1) WO1991006303A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
JP4429386B2 (en) * 1994-12-01 2010-03-10 生化学工業株式会社 Keratan sulfate oligosaccharide fraction and drug containing the same
EP0747470A1 (en) 1995-06-08 1996-12-11 The Procter & Gamble Company Cleaning compositions comprising keratanase
EP0747469A1 (en) * 1995-06-08 1996-12-11 The Procter & Gamble Company Cleaning compositions comprising chondroitinase
FR2787329B1 (en) * 1998-12-17 2001-02-09 Aventis Pharma Sa NEW THERAPEUTIC APPLICATION OF LOW MOLECULAR WEIGHT HEPARINS
AU6557299A (en) 1999-01-07 2000-07-13 Seikagaku Corporation Method for producing oligosaccharide, and novel oligosaccharide and pharaceutical composition containing the same
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
DE60008319T2 (en) 1999-07-21 2004-12-09 Seikagaku Corp. IL-12 production inhibitor
WO2002060471A2 (en) * 2001-01-30 2002-08-08 Ich Productions Limited Ligands for receptor-like protein tyrosine phosphatases
EP1425390B1 (en) 2001-08-13 2012-02-01 University of Florida Research Foundation, Inc. Materials and methods to promote repair of nerve tissue
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
JP2007532094A (en) 2003-05-16 2007-11-15 アコーダ セラピューティクス、インク． Proteoglycan-degrading mutant for CNS treatment
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
CA2566731C (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
WO2006111348A1 (en) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP5341756B2 (en) 2007-06-29 2013-11-13 国立大学法人名古屋大学 Agent for improving dysfunction based on neuropathy and inhibitor of Rho kinase activation
CA2729766A1 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
WO2011082175A2 (en) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Glycosaminoglycan inhibitors
EP3389674A4 (en) * 2015-12-18 2019-09-11 Tega Therapeutics, Inc. Cellular glycosaminoglycan compositions and methods of making and using

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5299207A (en) * 1976-02-16 1977-08-19 Kaken Pharmaceut Co Ltd Remedy for cattle diarrhea
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
SE8304836D0 (en) * 1983-09-09 1983-09-09 Pharmacia Ab SETTLE TO DETERMINE CHANGES IN LEDS
US4808570A (en) * 1984-02-24 1989-02-28 University Of California Compositions and method for improving wound healing
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4710493A (en) * 1984-08-14 1987-12-01 Albert Landsberger Therapeutic agent for the use in cancer treatment
DE3441835A1 (en) * 1984-11-15 1986-05-22 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Haemostatic composition
IT1208509B (en) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl PROCESS FOR THE PRODUCTION OF NATURALLY PURE NATURAL EPARAN SULPHATE AND DERMATAN SULPHATE AND THEIR PHARMACEUTICAL USE.
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4696816A (en) * 1985-11-07 1987-09-29 Brown Mark D Method for treating intervertebral disc displacement with enzymes
US4956348A (en) * 1986-02-19 1990-09-11 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with cyclic nucleotides
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
SE456245B (en) * 1986-07-09 1988-09-19 Pharmacia Ab ENZYME PREPARATION CONTAINING KRILLHYALURONIDAS
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
WO1991006303A1 (en) 1991-05-16
CA2071898A1 (en) 1991-04-28
EP0493533A4 (en) 1992-10-28
EP0493533A1 (en) 1992-07-08

Similar Documents

Publication Publication Date Title
AU6872691A (en) Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
AU6387590A (en) Door hinge
AU582138B2 (en) Refrigerator door hinge
AU633131B2 (en) Casement hinge
AU555747B2 (en) Chondroitin sulfate and sodium hyaluronate composition
AU2975892A (en) Methods of damping
AU6875191A (en) Wind turbine
AU581912B2 (en) Self closing hinge system
AU3797689A (en) Self-closing door sealing structure
AU7802187A (en) Flush mounted, fully concealed cabinet hinges
AU4805993A (en) Zirconium alloy with improved post-irradiation properties
AU2561792A (en) Cell-type specific heparan sulfate proteoglycans and their uses
AU9039991A (en) Heparan sulfate biosynthesis primers
AU6975991A (en) New acrylic copolymers and their application as coatings
AU5859890A (en) Hinge
AU628949B2 (en) Door hinge system
GB2244298B (en) Structural assemblies and cavity closers
AU5810690A (en) Heparin-producing murine mastocytoma cell lines
AU7720491A (en) Linerless closure
AU4594089A (en) Door closer
AU5915790A (en) Synthetic chondroitin sulfate proteoglycan and process for producing the same
AU1501988A (en) Door stop
GB8806244D0 (en) Cupboard door manufacture
AU6960391A (en) Heterocyclic substituted naphthyridinones and methods and compositions employing them
AU626105B2 (en) Temporary doorframe stay